Amgen Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Amgen Inc. (AMGN) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-02-14
- Amgen Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-12-31 was $0.00.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-09-30 was $0.00.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2021-12-31 was $0.00.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for fiscal 2021 was $1.50B.
- Amgen Inc. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $0.00 derived: sum of 2 quarters · filed 2024-02-14 | $0.00 derived: sum of 3 quarters · filed 2024-02-14 | $0.00 10-K · filed 2024-02-14 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-05 | $0.00 10-Q · filed 2022-08-05 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $0.00 derived: sum of 2 quarters · filed 2024-02-14 | $1.50B derived: sum of 3 quarters · filed 2024-02-14 | $1.50B 10-K · filed 2024-02-14 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 | $1.50B derived: sum of 2 quarters · filed 2022-11-04 | $1.50B 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $1.50B 10-Q · filed 2022-08-05 | $1.50B 10-Q · filed 2022-08-05 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $0.00 derived: sum of 2 quarters · filed 2023-02-09 | $0.00 derived: sum of 3 quarters · filed 2023-02-09 | $0.00 10-K · filed 2023-02-09 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |